Xarelto

Resources (English)

• Certification and Settlement Approval Hearing Notice (Canada, excluding Quebec residents)
• Settlement Approval Hearing Notice (Quebec)
• Class Action National Settlement Agreement
• Judgment on Notice Approval (Quebec)
• Judgment (Modification to Notice Program)
• Webex Virtual Courtroom Information
• Judgment (Settlement Approval)

Ressources (Français)

• Avis d'audience d'approbation du règlement (Canada, à l'exception du Québec)
• Avis d'audience d'approbation du règlement (Québec)
• Accord de règlement national des actions collectives
• Jugement sur l’avis d’approbation (Québec)
• Jugement modifié sur l'avis d'approbation (Québec)
• Informations sur la salle d’audience virtuelle Webex
• Jugement (approbation du règlement)
• Formulaire de réclamation

XARELTO ® LITIGATION: NOTICE OF SETTLEMENT APPROVAL

This Notice contains a summary of some of the terms of the Settlement Agreement. All capitalized terms not otherwise defined have the meaning ascribed to them in the Settlement Agreement. If there is a conflict between the provisions of this Notice and the Settlement Agreement, the terms of the Settlement Agreement shall prevail.

NOTICE OF SETTLEMENT APPROVAL

This is a notice for Class Members in the following Proceedings: Tluchak (Estate) et al. v. Bayer Inc. et al. , commenced in the Court of King’s Bench for Saskatchewan, Docket QBG-RG-00517-2015 and Gagnon c. Bayer inc. , commenced in the Cour supérieure du Québec, Court File No. 500-06-000732-152 (the “ Proceedings ”). The Proceedings raised various allegations against the Defendants and sought damages on behalf of all Canadians for harm and injuries which were allegedly related to the use of Xarelto®. The settlement of the Proceedings (the “ Settlement ”) has been approved by the Courts.

The Settlement applies to the following Class Members:

• Canadian residents, excluding residents of Québec, who were prescribed and ingested Xarelto® in Canada (“Primary Class Member”) before October 27, 2025 , and individuals who may make a claim pursuant to Family Compensation Legislation because of their relationship with a Primary Class Member (“Family Class Member”) (the “ Saskatchewan Class ”); and
• All persons residing in Québec who were prescribed and have ingested the drug Xarelto® (rivaroxaban) from January 1, 2008 to October 27, 2025 , and their successors, assigns, family members, and dependents (the “ Québec Class ”).

SUMMARY OF THE SETTLEMENT

The Settlement provides for the payment of at least $4,500,000 (CDN) which will be used to pay compensation for Approved Claims, Provincial Health Insurer Claims, Administration Expenses, Class Counsel Fees and Disbursements and any applicable taxes. Payments to approved Claimants will be made to Class Members who meet the criteria in the Compensation Protocol described below within the specified timeframes.

The Defendants deny all allegations and deny any wrongdoing or liability. The Courts have not taken any position on the merits of the arguments of either the Plaintiffs or the Defendants, but have determined that the Settlement Agreement is fair, reasonable, and in the best interests of the Class Members. A term of the Settlement is that the Proceedings will be dismissed or discontinued, which means that the lawsuit has come to an end, and there will be no trial.

PARTICIPATING IN THE SETTLEMENT

Class Members who satisfy the eligibility criteria set out in the Compensation Protocol may be entitled to benefits that will be calculated in accordance with the points system detailed in the Compensation Protocol.

Until all claims have been adjudicated, it will not be possible to determine the exact value of the compensation that may be paid to eligible Claimants.